LAVERDIA®-CA1
(verdinexor tablets)

The first conditionally approved oral tablet to treat lymphoma in dogs.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526

What does conditional approval mean?

For a veterinary drug to receive conditional approval, it must be shown to be safe when used according to the label. It must also demonstrate a “reasonable expectation of effectiveness,” but has not yet proven that it meets the “substantial evidence” standard of effectiveness for full approval. While a drug is conditionally approved it is not to be used for any extra-label species or indications.

In dogs, a seemingly healthy cell can mutate rapidly into B-cell lymphoma, a fatal disease.

Or a more aggressive T-cell lymphoma, also fatal, and even harder to treat.

To fight lymphoma and other diseases, tumor suppressor proteins (TSPs) naturally live inside the nucleus of all cells.

These tumor suppressors are responsible for suppressing cancer growth, and protecting healthy DNA

In healthy cells, transport proteins shuttle molecules out of the cell's nucleus to maintain balance and help the cell function

But in cancer cells, these transport proteins are produced in high volumes

A rapidly growing army of transport proteins seize TSPs...

...and shuttle them out of the cell, where they can no longer fight the advancement of cancer.

Without TSPs to protect the cell, cancer cells continue to grow and divide.

Laverdia®-CA1 blocks transport proteins to battle canine lymphoma

Laverdia®-CA1 selectively targets and binds to transport proteins. With Laverdia®-CA1 in a blocking position, transport proteins can no longer grab TSPs and export them from the nucleus.

Laverdia®-CA1 is the first and only canine cancer treatment that targets transport proteins.

TSPs build up inside the nucleus and the cancer cell dies

Laverdia®-CA1 kills lymphoma cells and helps slow the advance of cancer.

Unlike most cancer treatments, Laverdia®-CA1 generally spares healthy cells.

LAVERDIA®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.

Important Safety Information:
For use in dogs only. Laverdia®-CA1 (verdinexor tablets) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA®-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia®-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. LAVERDIA®-CA1 may affect female and male fertility. Wear protective disposable chemotherapy resistant gloves when handling Laverdia®-CA1 to avoid direct exposure to moistened, broken or crushed tablets or feces, urine, saliva or vomit from the treated dog. Do not use in dogs that are pregnant, nursing puppies or intended for breeding. Frequent check-ups by your veterinarian are necessary to determine whether your dog is responding to treatment, and to decide whether your dog should continue treatment with Laverdia®-CA1. The most commonly reported adverse reactions in dogs include decreased/loss of appetite, weight loss, vomiting, diarrhea, lethargy, excessive urination, excessive thirst, elevated liver enzymes, and low blood platelet count. Please see Client information Sheet and package insert for full product information.